Stephen J Kohut1, David S Jacobs2, Richard B Rothman3, John S Partilla3, Jack Bergman2, Bruce E Blough4. 1. McLean Hospital - Harvard Medical School, 115 Mill Street, Belmont, MA, 02478, USA. skohut@mclean.harvard.edu. 2. McLean Hospital - Harvard Medical School, 115 Mill Street, Belmont, MA, 02478, USA. 3. National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA. 4. Research Triangle Institute, Research Triangle Park, NC, USA.
Abstract
RATIONALE: The therapeutic potential of monoamine releasers with prominent dopaminergic effects is hindered by their high abuse liability. OBJECTIVES: The present study examined the effects of several novel "norepinephrine (NE)-preferring" monoamine releasers relative to non-selective monoamine releasers, d-amphetamine and d-methamphetamine, in rhesus monkeys trained to discriminate cocaine. NE-preferring releasers were approximately 13-fold more potent for NE compared to dopamine release and ranged in potency for serotonin release (PAL-329 < l-methamphetamine < PAL-169). METHODS: Adult rhesus macaques were trained to discriminate 0.4 mg/kg, IM cocaine on a 30-response fixed ratio schedule of food reinforcement. Substitution studies determined the extent to which test drugs produced cocaine-like discriminative stimulus effects and their time course. Drug interaction studies determined whether pretreatment with test drugs altered the discriminable effects of cocaine. RESULTS: Results show that cocaine, d-amphetamine, and d-methamphetamine dose-dependently substituted for cocaine with similar potencies. Among the "NE-preferring" releasers, PAL-329 and l-methamphetamine also dose-dependently substituted for cocaine but differed in potency. PAL-169 failed to substitute for cocaine up to a dose that disrupted responding. When administered prior to cocaine, only d-amphetamine and PAL-329 significantly shifted the cocaine dose-effect function leftward indicating enhancement of cocaine's discriminative stimulus effects. CONCLUSIONS: These data suggest that greater potency for NE relative to dopamine release (up to 13-fold) does not interfere with the ability of a monoamine releaser to produce cocaine-like discriminative effects but that increased serotonin release may have an inhibitory effect. Further characterization of these and other "NE-preferring" monoamine releasers should provide insight into their potential for the management of cocaine addiction.
RATIONALE: The therapeutic potential of monoamine releasers with prominent dopaminergic effects is hindered by their high abuse liability. OBJECTIVES: The present study examined the effects of several novel "norepinephrine (NE)-preferring" monoamine releasers relative to non-selective monoamine releasers, d-amphetamine and d-methamphetamine, in rhesus monkeys trained to discriminate cocaine. NE-preferring releasers were approximately 13-fold more potent for NE compared to dopamine release and ranged in potency for serotonin release (PAL-329 < l-methamphetamine < PAL-169). METHODS: Adult rhesus macaques were trained to discriminate 0.4 mg/kg, IM cocaine on a 30-response fixed ratio schedule of food reinforcement. Substitution studies determined the extent to which test drugs produced cocaine-like discriminative stimulus effects and their time course. Drug interaction studies determined whether pretreatment with test drugs altered the discriminable effects of cocaine. RESULTS: Results show that cocaine, d-amphetamine, and d-methamphetamine dose-dependently substituted for cocaine with similar potencies. Among the "NE-preferring" releasers, PAL-329 and l-methamphetamine also dose-dependently substituted for cocaine but differed in potency. PAL-169 failed to substitute for cocaine up to a dose that disrupted responding. When administered prior to cocaine, only d-amphetamine and PAL-329 significantly shifted the cocaine dose-effect function leftward indicating enhancement of cocaine's discriminative stimulus effects. CONCLUSIONS: These data suggest that greater potency for NE relative to dopamine release (up to 13-fold) does not interfere with the ability of a monoamine releaser to produce cocaine-like discriminative effects but that increased serotonin release may have an inhibitory effect. Further characterization of these and other "NE-preferring" monoamine releasers should provide insight into their potential for the management of cocaine addiction.
Entities:
Keywords:
Cocaine use disorder; Dopamine; Drug discrimination; Monoamine releaser; Non-human primate; Norepinephrine
Authors: Sunmee Wee; Zhixia Wang; Rong He; Jia Zhou; Alan P Kozikowski; William L Woolverton Journal: Drug Alcohol Depend Date: 2005-10-05 Impact factor: 4.492
Authors: Debra A Cooper; Heather L Kimmel; Daniel F Manvich; Karl T Schmidt; David Weinshenker; Leonard L Howell Journal: J Pharmacol Exp Ther Date: 2014-05-09 Impact factor: 4.030
Authors: M T Bardo; E D Denehy; L R Hammerslag; L P Dwoskin; B E Blough; A Landavazo; J Bergman; S J Kohut Journal: Psychopharmacology (Berl) Date: 2019-07-26 Impact factor: 4.530
Authors: Bruce E Blough; Ann M Decker; Antonio Landavazo; Ojas A Namjoshi; John S Partilla; Michael H Baumann; Richard B Rothman Journal: Psychopharmacology (Berl) Date: 2018-10-20 Impact factor: 4.530
Authors: Fernando B de Moura; Alexander Sherwood; Thomas E Prisinzano; Carol A Paronis; Jack Bergman; Stephen J Kohut Journal: Pharmacol Biochem Behav Date: 2021-01-12 Impact factor: 3.533